Omeros (NASDAQ: OMER) has announced that it has completed its first commercial shipments of YARTEMLEA to distributors for the treatment of adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
According to Omeros, the commercial orders were completed last week, with additional orders from transplant centers beginning the same day. Adult and pediatric patients are now receiving YARTEMLEA, including those who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpatient settings.
YARTEMLEA was FDA-approved in December 2025, and is the first and only approved therapy for TA-TMA, an often-fatal complication of stem cell transplantation driven by activation of the lectin pathway of complement.
